Abstract | AIM: METHODS: Patients were treated with four therapeutic cycles alternating [(177)Lu] DOTA-TATE (5.55 GBq) and [(90) Y]DOTA-TATE (2.6 GBq). Dosimetric evaluation after administration of [(177)Lu] DOTA-TATE allows to calculate the absorbed doses in healthy organs. Blood samples were collected at 5 min, 1, 6, 24, 48, 72, 96 h and scintigraphy was performed once a day for four days after administration. Toxicity was evaluated considering hematological parameters and renal toxicity was evaluated also by the glomerular filtration rate (GFR). Efficacy related with RECIST criteria. RESULTS: Up to now 26 patients entered the study and 16 patients completed all cycles. Treatment was well tolerated with no adverse event registered. No damage to healthy organs was revealed in accordance with the calculated absorbed doses. We had a partial response in 10/15 patients evaluated three months after the fourth treatment. CONCLUSIONS: Up to now only a few patients participated in and concluded this study; preliminary results are encouraging and indicate the feasibility of the study.
|
Authors | E Seregni, M Maccauro, A Coliva, M R Castellani, E Bajetta, G Aliberti, C Vellani, C Chiesa, A Martinetti, A Bogni, E Bombardieri |
Journal | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
(Q J Nucl Med Mol Imaging)
Vol. 54
Issue 1
Pg. 84-91
(Feb 2010)
ISSN: 1824-4785 [Print] Italy |
PMID | 20168290
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-
- Organometallic Compounds
- lutetium Lu 177 dotatate
- Octreotide
|
Topics |
- Adult
- Aged
- Drug Therapy, Combination
- Humans
- Male
- Middle Aged
- Neuroendocrine Tumors
(pathology, radiotherapy, therapy)
- Octreotide
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Organometallic Compounds
(administration & dosage, adverse effects, therapeutic use)
- Radiometry
- Treatment Outcome
|